Commentary

Article

State of the Science Summit - Hematology: Chaired by Martha Arellano, MD

State of the Science Summit - Hematology: Chaired by Martha Arellano, MD

State of the Science Summit - Hematology: Chaired by Martha Arellano, MD

Speakers

  • Martha Arellano, MD | Winship Cancer Institute of Emory University
  • Anthony Hunter, MD | Winship Cancer Institute of Emory University
  • Michael Hochman, MD| Winship Cancer Institute of Emory University
  • Nikolaos Papadantonakis, MD, PhD| Winship Cancer Institute of Emory University
  • Jean Koff, MD, MS| Winship Cancer Institute of Emory University
  • Jason Romancik, MD| Winship Cancer Institute of Emory University
  • Nisha Joseph, MD| Winship Cancer Institute of Emory University

Topics

  • Managing Patients with Myelofibrosis
  • Emerging Treatment Standards for MDS
  • BTK Inhibition in MCL and CLL
  • Bispecific Antibodies in DLBCL
  • Updates in AML
  • Live Q&A

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study